Isomorphic Labs raises $5 billion to accelerate AI-driven drug development
Original headline: Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO
Isomorphic Labs, founded by former DeepMind CEO Demis Hassabis, secured a $5 billion funding round just six months after its previous mega‑round. The capital will be used to develop new medicines by leveraging artificial intelligence to discover drug candidates and move them into clinical trials.
The infusion of massive funding into AI‑driven drug discovery could speed up the delivery of new medicines to patients.
Research angleHow does AI‑assisted drug candidate identification affect R&D efficiency in pharmaceutical firms? — Diffusion of Innovations theory
2 related reports
This story could become your next paper
HJITM works with researchers from study design through surveys, analysis and submission to international journals in generative AI and technology management. Bring us your research question.
This item is an AI-generated summary of reporting by CNBC. Please check the original article for accuracy. Copyright in the original article belongs to CNBC.